Patents Assigned to Allergan Pharmaceuticals
  • Patent number: 10251885
    Abstract: The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions are capable of treating an infection caused by fungi, such as onychomychosis.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: April 9, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Jon Lenn, Hans Hofland, Edward Hsia
  • Patent number: 10206882
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 19, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 10184121
    Abstract: Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 22, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Luigi Ghidorsi
  • Patent number: 10016442
    Abstract: Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: July 10, 2018
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: David Woolfson, Karl Malcolm
  • Patent number: 9993424
    Abstract: The present invention relates to a process for the preparation of an intravaginal matrix drug delivery device. The process comprises the steps of combining at least one therapeutic agent in a therapeutically effective amount with at least one biocompatible elastomeric polymer to form a mix; curing said mix in a mold having a shape of said intravaginal drug delivery device, to form a polymer matrix; and maturing said polymer matrix to form the intravaginal drug delivery device. The maturing step alters the release rate characteristics of a device prepared in accordance with the process of the invention.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: June 12, 2018
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Colin Lorimer, Claire Gilligan
  • Patent number: 9976171
    Abstract: The invention is directed to a process for measuring the amount of digestive enzymes released from a solid composition in a dissolution medium by fluorescence spectroscopy. The invention is also directed to a combined method for measuring both the dissolution and gastroresistance of a solid compositions comprising pancrelipase.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: May 22, 2018
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Massimo Latino, Luigi Ghidorsi, Giovanni Ortenzi
  • Patent number: 9908682
    Abstract: Ampoules made of plastics material and containing 0.5 to 5 ml of a pharmaceutical formulation are sealed, together with an oxygen scavenger, within a pouch.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: March 6, 2018
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Ian Gardener Cameron McAffer, Peter Ernest Tasko
  • Patent number: 9820946
    Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 21, 2017
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
  • Patent number: 9795569
    Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 24, 2017
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
  • Patent number: 9763887
    Abstract: A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 19, 2017
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Ryan Gerald Loughlin, Stephen McCullagh, Roger Boissonneault
  • Patent number: 4790846
    Abstract: A method of making an intraocular lens including providing a fixation member having a proximal end portion with the proximal end portion including an elongated filament, converting a region of said filament at said proximal end portion from a first configuration into a second configuration which is adapted to provide a mechanical interlock and molding an optic about the proximal end portion of the fixation member to form a mechanical interlock between the second configuration and the optic and to attach the fixation member to the optic.
    Type: Grant
    Filed: September 15, 1987
    Date of Patent: December 13, 1988
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: F. Richard Christ, Dean K. Pettit, Jeffrey C. Day
  • Patent number: 4743588
    Abstract: Compositions and methods useful for enhancing the transdermal and transmembrane drug delivery of topical and systemic agents. The compositions and methods comprise the active agent together with an effective amount of certain amides of heterocyclic amines as defined herein as penetration enhancers and topically administering to human or animal skin or other membranes the resulting compositions.
    Type: Grant
    Filed: June 13, 1984
    Date of Patent: May 10, 1988
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: Dorla Mirejovsky, Harun Takruri
  • Patent number: 4670178
    Abstract: A one step method for cleaning and disinfecting contact lenses is accomplished by immersing the lenses in a solution containing peroxide and a peroxide-active enzyme.
    Type: Grant
    Filed: September 9, 1985
    Date of Patent: June 2, 1987
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: Stanley W. Huth, Sam W. Lam, Richard M. Kiral
  • Patent number: 4524063
    Abstract: A topical lodoxamide composition having enhanced efficacy for treatment of ocular allergic diseases. The composition comprises the addition of polyvinyl alcohol to an aqueous solution containing lodoxamide tromethamine.
    Type: Grant
    Filed: December 22, 1983
    Date of Patent: June 18, 1985
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventor: Larry A. Wheeler
  • Patent number: 4460573
    Abstract: A method of preparing solutions containing thimerosal and polyvinylpyrrolidone which results in improved stability of thimerosal is disclosed. The method involves applying a certain amount of heat to the polyvinylpyrrolidone while it is in aqueous solution and prior to its combination with thimerosal. The required thermal input to the polyvinylpyrrolidone solution is a function of four variables: solution temperature, heating time, external pressure and polyvinylpyrrolidone concentration. Advantageously this method may be employed in the manufacture of contact lens solutions.
    Type: Grant
    Filed: June 22, 1983
    Date of Patent: July 17, 1984
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: Stanley W. Huth, Hali G. Wagner
  • Patent number: 4395346
    Abstract: A method and composition for the treatment of contact lenses, and especially soft contact lenses such as silicone and hydrophilic plastic contact lenses to remove inorganic deposits. The method consists of treating a contact lens with an aqueous solution containing an effective amount of a sequestering agent, such as a polymetaphosphate, gluconic acid or salts thereof. A preferred polymetaphosphate is sodium hexametaphosphate.
    Type: Grant
    Filed: November 18, 1981
    Date of Patent: July 26, 1983
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventor: Frederick D. Kleist
  • Patent number: 4255419
    Abstract: Low serum zinc concentrations in humans have been associated with multiple sclerosis in some patients, particularly those patients under 50 years of age. Increasing the concentration of serum zinc in such patients has been found to lower the number of, or decrease the severity of recurrent attacks and/or improve neurologic function in some patients.
    Type: Grant
    Filed: September 27, 1979
    Date of Patent: March 10, 1981
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventor: Irving H. Leopold
  • Patent number: 4244948
    Abstract: A method for topically treating inflammation in humans or animals by administering to the inflamed area a therapeutically effective amount of an alkyl- or aralkyl-substituted acetylsalicylic acid such as methyl-, ethyl-, allyl- or benzyl acetylsalicylate. The method may also be used to treat acne by applying a therapeutically effective amount of the acetylsalicylate ester to the affected skin in a human having skin affected by acne.
    Type: Grant
    Filed: May 7, 1979
    Date of Patent: January 13, 1981
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: Malcolm P. Boghosian, Robert T. Koda
  • Patent number: 4230724
    Abstract: A method of treating vascularization of the eye as a result of traumatic injury, surgery, such as, corneal transplant, or onset of diabetic retinopathy by topically treating the eye with Flurbiprofen or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 16, 1979
    Date of Patent: October 28, 1980
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventors: Charles A. Cooper, Michael V. W. Bergamini
  • Patent number: D279357
    Type: Grant
    Filed: May 20, 1983
    Date of Patent: June 25, 1985
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventor: David W. Mitchell